Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used to treat erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but less selectivity than tadalafil, suggesting a relatively lower risk of visual disturbances...
- Mechanism
- Curator reviewed · 4 references
Avanafil inhibits the cGMP-specific phosphodiesterase type 5 (PDE5) which is responsible for the degradation of cGMP in the corpus cavernosum located around the penis. Sexual arousal results in the local release of nitric oxide, which in turn stimulates the enzyme guanylate cyclase to produce cGMP. Elevated levels of cGMP result in local smooth muscle relaxation and increased blood flow to the penis (i.e. an erection).
As PDE5 inhibitors like avanafil require the endogenous release of nitric oxide in order to exert their pharmacologic effect, they have no effect on the user in the absence of sexual stimulation/arousal.
- Primary indication
- Avanafil is indicated for the treatment of erectile dysfunction.Curator reviewed · 1 structured indication
- Formula / weight
- C23H26ClN7O3 · 483.951 g/mol (avg)
- First approval
- United States, 2013 · European Union, 2016
- Code names
- TA-1790
- Brand names
Resolves to
WEAJZXNPAWBCOA-INIZCTEOSA-NSMILESCOC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1What you can answer from here — as of October 27, 2022
Which drugs share a target with Avanafil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account